4596 related articles for article (PubMed ID: 6263475)
1. Implanted system for intraventricular drug infusion in central nervous system tumors.
Dakhil S; Ensminger W; Kindt G; Niederhuber J; Chandler W; Greenberg H; Wheeler R
Cancer Treat Rep; 1981; 65(5-6):401-11. PubMed ID: 6263475
[TBL] [Abstract][Full Text] [Related]
2. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
3. Treatment of central nervous system tumors with methotrexate.
Abelson HT; Kufe DW; Skarin AT; Major P; Ensminger W; Beardsley GP; Canellos GP
Cancer Treat Rep; 1981; 65 Suppl 1():137-40. PubMed ID: 6976830
[TBL] [Abstract][Full Text] [Related]
4. Severe complications after intrathecal methotrexate (MTX) for treatment of primary central nervous system lymphoma (PCNSL).
Weigel R; Senn P; Weis J; Krauss JK
Clin Neurol Neurosurg; 2004 Mar; 106(2):82-7. PubMed ID: 15003295
[TBL] [Abstract][Full Text] [Related]
5. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
Hiraga S; Arita N; Ohnishi T; Kohmura E; Yamamoto K; Oku Y; Taki T; Sato M; Aozasa K; Yoshimine T
J Neurosurg; 1999 Aug; 91(2):221-30. PubMed ID: 10433310
[TBL] [Abstract][Full Text] [Related]
6. [Local chemotherapy for malignant brain tumors using methotrexate-containing fibrin glue].
Hirakawa W; Kadota K; Asakura T; Niiro M; Yokoyama S; Hirano H; Yatsushiro K; Kubota Y; Shimodozono Y
Gan To Kagaku Ryoho; 1995 May; 22(6):805-9. PubMed ID: 7755389
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors.
Glantz MJ; Jaeckle KA; Chamberlain MC; Phuphanich S; Recht L; Swinnen LJ; Maria B; LaFollette S; Schumann GB; Cole BF; Howell SB
Clin Cancer Res; 1999 Nov; 5(11):3394-402. PubMed ID: 10589750
[TBL] [Abstract][Full Text] [Related]
8. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid.
McCully CL; Balis FM; Bacher J; Phillips J; Poplack DG
Lab Anim Sci; 1990 Sep; 40(5):520-5. PubMed ID: 2170754
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetics of intrathecal chemotherapy and clinical problems].
Fujimoto T
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1536-42. PubMed ID: 6433796
[TBL] [Abstract][Full Text] [Related]
10. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial.
Laver JH; Kraveka JM; Hutchison RE; Chang M; Kepner J; Schwenn M; Tarbell N; Desai S; Weitzman S; Weinstein HJ; Murphy SB
J Clin Oncol; 2005 Jan; 23(3):541-7. PubMed ID: 15659500
[TBL] [Abstract][Full Text] [Related]
11. [Primary central nervous system lymphoma--a report of 32 cases with literature review].
Yi JQ; Lin TY; He YJ; Huang HQ; Xia ZJ; Xia YF; Xu RH; Guo Y; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):476-80. PubMed ID: 16613684
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. Active transport of methotrexate from cerebrospinal fluid in humans.
Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
15. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
16. A pilot study of high-dose 1-beta-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology.
Early AP; Preisler HD; Slocum H; Rustum YM
Cancer Res; 1982 Apr; 42(4):1587-94. PubMed ID: 6949642
[TBL] [Abstract][Full Text] [Related]
17. Monitoring central nervous system methotrexate levels via subcutaneous reservoir. Sources of errors in sampling and their avoidance.
Maguire LC; Corder MP; Wiesenfeld M
Cancer Clin Trials; 1980; 3(4):337-40. PubMed ID: 6893574
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
19. First human treatment of resistant neoplastic meningitis by intrathecal administration of MTX plus (125)IUdR.
Rebischung C; Hoffmann D; Stefani L; Desruet MD; Wang K; Adelstein SJ; Artignan X; Vincent F; Gauchez AS; Zhang H; Fagret D; Vuillez J; Kassis AI; Balosso J
Int J Radiat Biol; 2008 Dec; 84(12):1123-9. PubMed ID: 19061137
[TBL] [Abstract][Full Text] [Related]
20. [Intrathecal infusion of the antineoplastic agents for meningeal dissemination].
Hodozuka A; Hayashi Y; Annei R; Hiroshima S; Saito M; Orimoto R; Sato M; Tanaka T
Gan To Kagaku Ryoho; 2008 Jun; 35(6):900-5. PubMed ID: 18633217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
